Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Clene ( (CLNN) ).
Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.
For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.